LitAlert ~~ GeneLit.com

    • Epidemiologic evidence of exposure to polycyclic aromatic hydrocarbons and breast cancer: A systematic review and meta-analysis.
    • Gamboa-Loira B, López-Carrillo L, Mar-Sánchez Y, Stern D, Cebrián ME.
    • Chemosphere. 2021 Dec 17:133237. doi: 10.1016/j.chemosphere.2021.133237. Epub ahead of print.
    • Review
    • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer.
    • Navitski A, Al-Rawi DH, Liu Y, Rubinstein MM, Friedman CF, Rampal RK, Mandelker DL, Cadoo K, O'Cearbhaill RE.
    • Gynecol Oncol Rep. 2021 Oct 5;38:100873. doi: 10.1016/j.gore.2021.100873. eCollection 2021 Nov.
    • The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).
    • Rose PG, Yao M, Chambers LM, Mei L, Le P.
    • Gynecol Obstet (Sunnyvale). 2021;11(9):570. Epub 2021 Oct 7.
    • To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
    • Rose PG, Chambers LM, Kuznicki M.
    • Gynecol Obstet (Sunnyvale). 2021;11(7):561. Epub 2021 Aug 3.